Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
In recent years, researchers have developed a variety of tools to help men and their doctors decide whether they need a prostate biopsy or what their outcome might be after a specific type of treatment for prostate cancer. However, the researchers who built these tools also have a sincere and serious appreciation of the limitations [...]
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: decision analysis, outcome, risk | Leave a Comment »
This morning’s news reports address: Patterns of use of PSA and DRE testing in the USA The value of ADT in men receiving combined brachytherapy + EBRT Skeletal and cardiovascular adverse effects of ADT LHRH agonist treatment and effects on LHRH agonist receptors
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, DRE, LHRH agonist, mechanism of action, pattens of use, PSA | Leave a Comment »
A newly published study appearing in the Journal of the American Board of Family Medicine appears to demonstrate that patients newly diagnosed with localized prostate cancer grossly underestimate their life expectancy without treatment and grossly overestimate the survival benefit of treatment.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: expectation, localized, outcome, patient, prostate cancer, Treatment | 10 Comments »
The whole issue of the appropriateness of cancer screening is starting to become a major public health issue, closely and inevitably associated with cancer risk.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: controversy, Prevention, risk, screening | 4 Comments »
Today’s news reports include information on: Outcomes comparing two types of radiation therapy Outcomes of younger vs. older men after radical prostatectomy The activity and safety of AZD0530 in CRPC
Filed under: Drugs in development, Management, Treatment | Tagged: AZD0530, conformal beam, hypofractionated, old, radiotherapy, raduical prostatectomy, standard, young | Leave a Comment »
There is an increasing belief among at least some opinion-leaders in the prostate cancer treatment community that androgen deprivation therapy has been and still is being significantly overused.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, hormone, therapy | 1 Comment »
According to a report today on NJ.com, there are suggestions that defective “autophagy” — the process through which a cell “self-digests” because of the action of enzymes originating within the same cell — may be crucial to the amount and aggressiveness of at least some cancers. Prostate cancer may be one of those types of [...]
Filed under: Drugs in development, Management, Prevention | Leave a Comment »
Historically (by which we mean back in the 1980s and earlier) there was a well-recognized and significant risk of mortality associated with radical prostatectomy (RP), which was seen at that time as a difficult and “bloody” procedure with a well-understood series of risks for significant complications. The risk of mortality directly associated with the procedure [...]
Filed under: Management, Treatment | Tagged: mortality, radical prostatectomy | Leave a Comment »
An Italian study has reported data from a retrospective analysis of outcomes after radical surgery and external beam radiation therapy (EBRT) + androgen deprivation therapy (ADT) in first-line treatment of two, pre-treatment-defined, concurrently treated, high-risk patient populations, all treated at a single institution between January 2003 and December 2007.
Filed under: Management, Treatment | Tagged: "high risk", comparison, radiation, surgery | 2 Comments »
Todays news reports adddress: Surgeon and hospital volume and outcomes to radical prostatectomy Adverse events associated with the use of hypofractionated, dose-escalated, IMRT Quality of sexual function after external beam radiation therapy Percentage of positive biopsy cores and response to first-line hormone therapy
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, core, EBRT, external beam radiation therapy, hormone therapy, hospital, hypofractionated, IMRT, radical prostatectomy, sexual function, surgeon, volume | Leave a Comment »
Today’s prostate cancer news report deals with: A recent review of appropriate penile rehabilitation strategies Management of biochemical recurrence after first-line treatment failure Initial use of hormone therapy by French clinicians
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical recurrence, hormone therapy, penile rehabilitation, radiation therapy, surgery | Leave a Comment »
There are several recent reports that address factors specific to the combination of hormone therapy with radiation therapy in the management of prostate cancer, so we thought it would be helpful to offer a topical update.
Filed under: Management, Treatment | Tagged: adjuvant, androgen deprivation, hormone therapy, neoadjuvant, radiotherapy | 1 Comment »
An important article by Bolla et al. has been published in the New England Journal of Medicine today, together with editorial comment by Albertsen. We advise readers to study this article in conjunction with a second article published today under the heading “Hormone therapy and radiation treatment: a topical update.”
Filed under: Management, Treatment | Tagged: adjuvant, hormone, locally advanced, radiation, therapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site